The consortium was a collaboration between the Carpenter-Singh Lab, the Genetic Perturbation Platform, and the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard along with industry and non-profit partners that were committed to creating a public Cell Painting dataset containing both genetic and chemical perturbations. With such a resource, each company or institution can now create its own proprietary Cell Painting data in-house, while matching their profiles against the public set, to guide small molecules’ progression to the clinic.

Non-profit partners:

• Broad Institute of MIT and Harvard
• Ksilink

Pharma partners:

• Amgen
• AstraZeneca
• Bayer
• Biogen
• Eisai
• Janssen Pharmaceutica NV
• Merck KGaA, Darmstadt, Germany
• Pfizer
• Servier
• Takeda Pharmaceutical Company Limited (“Takeda”)

Supporting partners:

• Ardigen
• Google Research
• Revvity (Dharmacon)
• Nomic
• Revvity
• Verily

JUMP also had Collaborators working on this project.